Corporate Profile

Aeterna Zentaris Inc. (TSX: AEZ, NASDAQ: AEZS) is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health.

Contact us:

Aeterna Zentaris Inc.
1405 du Parc-Technologique Blvd.
Québec, Québec
G1P 4P5
Phone: (418) 652-8525
Fax: (418) 948-9191

Aeterna Zentaris, Inc.
315 Sigma Drive, Suite 302D
Summerville, SC 29483
Phone: (843) 900-3223

Aeterna Zentaris GmbH
Weismüllerstrasse 50
60314 Frankfurt
Phone: +49 69 42602 3228

Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York more...>

Aeterna Zentaris Reports Second Quarter Financial and Operating Results more...>

Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October more...>

Aeterna Zentaris to Announce Second Quarter 2015 Financial and Operating Results on August 13, 2015 more...>

Aeterna Zentaris to Present at Upcoming Canaccord Genuity 35th Annual Global Growth Conference in Boston more...>

Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development more...>

Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology more...>

Aeterna Zentaris Commences Promotional Activities for EMD Serono’s Saizen® [Somatropin (rDNA origin) for Injection] more...>

Aeterna Zentaris Completes Patient Recruitment for ZoptEC Phase 3 Study with Zoptarelin Doxorubicin in Advanced Endometrial Cancer more...>

Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen™ in AGHD more...>

Aeterna Zentaris Announces Extension to Regain Compliance with NASDAQ's Minimum Bid Price Rule more...>

Aeterna Zentaris’ Confirmatory Phase 3 Study for Macrilen™ in AGHD Meets EMA’s Study-Design Expectations more...>

Aeterna Zentaris Announces Election of Directors at 2015 Shareholders’ Meeting more...>

Aeterna Zentaris and EMD Serono Finalize Promotional Services Agreement for Saizen® [Somatropin (rDNA origin) for Injection] in the U.S. more...>

Aeterna Zentaris Reports 1st Quarter 2015 Financial and Operating Results more...>
May 8, 2015
First quarter 2015 financial and operating results


Download PDF (125K)
Download and install Acrobat Reader